What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

What have we learned from the START trial of immunotherapy in locally advanced NSCLC?

Da: GRACEcast
0 0 7 anni fa
Drs. Nate Pennell, Mary Pinder, and Jack West discuss the START trial of L-BLP-25 (tecemotide) immunotherapy in locally advanced NSCLC.

Seguici su Facebook